KOSPI Pharmaceuticals Index Market Cap Rebounds Above KRW 140 Trillion

[NEWSMP] The combined market capitalization of the KOSPI Pharmaceuticals Index's constituent stocks rebounded above KRW 140 trillion, driven by Samsung Biologics and Celltrion.

According to the Korea Exchange, the combined market capitalization of the 49 constituent stocks of the KOSPI Pharmaceuticals Index, excluding preferred shares, stood at KRW 141.3268 trillion at the close of trading on October 30, an increase of KRW 5.5658 trillion from the end of September.

However, during this period, share prices declined for 38 of the 49 index constituents, while only 10 recorded gains.

Among the gainers, Daewon Pharmaceutical posted a double-digit monthly gain of 12.6%, bolstered by a 12.7% surge in its share price on the final trading day of the month.

Daewon Pharmaceutical was the only stock to post a double-digit monthly gain. Celltrion rose 7.8%, Samsung Biologics gained 6.9%, and GC Biopharma climbed 5.9%, bringing the number of stocks that gained more than 5% to four.

Shares of Whanin Pharmaceutical, Kukje Pharma, Yuhan Corporation, Samjin Pharmaceutical, Dong Wha Pharmaceuticals, and Daewoong also posted modest gains.

In contrast, shares of Orient Bio and Hyundai Pharmaceutical plunged more than 20% over the same period. Samyang Biopharm, Hanmi Pharmaceutical, and HanAll Biopharma fell more than 15%, while Jeil Pharmaceutical, JW Pharmaceutical, and IL-Yang Pharmaceutical also recorded double-digit declines.

Shares of Ildong Pharmaceutical, SK Bioscience, Aprogen Biologics, Yungjin Pharm, Bukwang Pharmaceutical, Myungmoon Pharm, Shin Poong Pharm, Samsung Pharmaceutical, Reyon Pharmaceutical, Dongsung Pharmaceutical, and Myung In Pharm also declined by more than 5%.

Meanwhile, Samsung Biologics' market capitalization increased by KRW 4.4439 trillion over the month, while Celltrion's rose by KRW 3.1291 trillion. Together, the two companies drove the overall increase in the index's market capitalization. Yuhan Corporation's market capitalization also increased by more than KRW 100 billion.

By contrast, Hanmi Pharmaceutical's market capitalization declined by KRW 1.0761 trillion, while HanAll Biopharma and SK Bioscience saw decreases of KRW 344.8 billion and KRW 262.8 billion, respectively.

At the end of October, Samsung Biologics had the largest market capitalization at KRW 68.8346 trillion, followed by Celltrion at KRW 44.4652 trillion. Yuhan Corporation overtook Hanmi Pharmaceutical, with its market capitalization reaching KRW 5.5285 trillion, compared with Hanmi Pharmaceutical's KRW 5.3166 trillion.

Other pharmaceutical companies with market capitalizations exceeding KRW 1 trillion included SK Bioscience at KRW 2.5695 trillion, HanAll Biopharma at KRW 1.9590 trillion, GC Biopharma at KRW 1.5216 trillion, and Daewoong Pharmaceutical at KRW 1.1714 trillion.